We are pleased to announce that Linnaeus Therapeutics is the latest company to join the Kairos portfolio. Linnaeus Therapeutics is a development stage biotech company engaged in the identification and development of small molecule agents that modulate cellular differentiation for the treatment of cancer and disorders of pigmentation.

“We are extremely excited to be working with Kairos and have them lead our Series A round. This critical funding will allow us to advance our drug-candidate, LNS8801, toward our first-in-human studies.”
– Patrick Mooney, M.D., CEO of Linnaeus Therapeutics, Inc.

Founded in 2016 and headquartered in Philadelphia, Linnaeus Therapeutics was launched through the UPstart incubator at the University of Pennsylvania’s Penn Center for Innovation (PCI) Ventures. Linnaeus has licensed key enabling worldwide patents from the University of Pennsylvania (“Penn”) and the University of New Mexico (“UNM”) for compounds and methods for the treatment of cancer. Linnaeus has also filed patents of its own on its lead compound LNS8801, which extend the value of Linnaeus’s licensed patent portfolio. Linnaeus is also currently focusing on developing small molecules that activate other G protein-coupled receptors to engage tumor-suppressive cellular signaling pathways.

With the funding provided by Kairos, Linnaeus will advance their drug-candidate, LNS8801, toward first-in-human studies. As part of the investment, Nikos Iatropoulos has joined the Linnaeus Board. “We are extremely excited to be working with Kairos and have them lead our Series A round,” said Patrick Mooney, M.D., CEO of Linnaeus Therapeutics. “This critical funding will allow us to advance our drug-candidate, LNS8801, toward our first-in-human studies, which we anticipate commencing next year. The early data appear very promising, and we are thrilled to welcome them to the Linnaeus team.”

We are excited about our investment in Linnaeus Therapeutics and welcome them to the extended Kairos Ventures family!